Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1929 1
1947 1
1950 4
1951 1
1953 7
1954 2
1955 1
1956 1
1961 2
1962 6
1963 8
1964 13
1965 7
1966 16
1967 19
1968 10
1969 11
1970 13
1971 16
1972 18
1973 17
1974 20
1975 16
1976 18
1977 25
1978 19
1979 18
1980 18
1981 18
1982 31
1983 34
1984 32
1985 41
1986 30
1987 45
1988 47
1989 58
1990 51
1991 38
1992 53
1993 49
1994 52
1995 68
1996 77
1997 62
1998 54
1999 62
2000 61
2001 52
2002 59
2003 57
2004 78
2005 77
2006 105
2007 127
2008 134
2009 132
2010 149
2011 173
2012 199
2013 207
2014 193
2015 240
2016 209
2017 250
2018 279
2019 282
2020 344
2021 441
2022 427
2023 467
2024 539
2025 434
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,354 results

Results by year

Filters applied: . Clear all
Page 1
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, Ocio EM, Yoon SS, Chu MP, Rodríguez-Otero P, Avivi I, Quijano Cardé NA, Kumar A, Krevvata M, Peterson MR, Di Scala L, Scott E, Hilder B, Vanak J, Banerjee A, Oriol A, Morillo D, Mateos MV; RedirecTT-1 Investigators and Study Group. Cohen YC, et al. Among authors: banerjee a. N Engl J Med. 2025 Jan 9;392(2):138-149. doi: 10.1056/NEJMoa2406536. N Engl J Med. 2025. PMID: 39778168 Clinical Trial.
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Martin T, et al. Among authors: banerjee a. J Clin Oncol. 2023 Feb 20;41(6):1265-1274. doi: 10.1200/JCO.22.00842. Epub 2022 Jun 4. J Clin Oncol. 2023. PMID: 35658469 Free PMC article.
Managing Carious Lesions: Consensus Recommendations on Terminology.
Innes NP, Frencken JE, Bjørndal L, Maltz M, Manton DJ, Ricketts D, Van Landuyt K, Banerjee A, Campus G, Doméjean S, Fontana M, Leal S, Lo E, Machiulskiene V, Schulte A, Splieth C, Zandona A, Schwendicke F. Innes NP, et al. Among authors: banerjee a. Adv Dent Res. 2016 May;28(2):49-57. doi: 10.1177/0022034516639276. Adv Dent Res. 2016. PMID: 27099357
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S. Miao X, et al. Among authors: banerjee a. Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15. Target Oncol. 2023. PMID: 37713090 Free PMC article.
Verification bias.
O'Sullivan JW, Banerjee A, Heneghan C, Pluddemann A. O'Sullivan JW, et al. Among authors: banerjee a. BMJ Evid Based Med. 2018 Apr;23(2):54-55. doi: 10.1136/bmjebm-2018-110919. Epub 2018 Feb 27. BMJ Evid Based Med. 2018. PMID: 29595130
Hereditary Angioedema.
Banerjee A, Bermudez N, Gould MB, Ramlatchan SR, Ganti L. Banerjee A, et al. Cureus. 2023 Jul 18;15(7):e42088. doi: 10.7759/cureus.42088. eCollection 2023 Jul. Cureus. 2023. PMID: 37602066 Free PMC article.
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.
Harrison SJ, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, Rahman M, Le Bris Y, Er J, Eugene-Lamer J, Haynes NM, Li J, Abbott RC, Bodet-Milin C, Moreau A, Letouzé E, Lendvai N, Schecter JM, Deraedt W, Banerjee A, Lengil T, Vogel M, Foulk B, Zhao H, Smirnov D, Slaughter A, Lonardi C, Lee E, Marquez L, Sankari A, Plaks V, Filho JOC, Patel N, Geng D, Gastinne T, Kelly H, Tiong IS, Eveillard M, Chevallier P, Lade S, Moreau P, Grimmond S, Oliaro J, Tessoulin B, Blombery P. Harrison SJ, et al. Among authors: banerjee a. N Engl J Med. 2025 Feb 13;392(7):677-685. doi: 10.1056/NEJMoa2309728. N Engl J Med. 2025. PMID: 39938094
Recognising obstetric emergencies.
Banerjee A, Yulia A. Banerjee A, et al. Case Rep Womens Health. 2025 Feb 12;46:e00695. doi: 10.1016/j.crwh.2025.e00695. eCollection 2025 Jun. Case Rep Womens Health. 2025. PMID: 40568527 Free PMC article. No abstract available.
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. Among authors: banerjee a. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
6,354 results